We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Immunogenicity of standard, high-dose, MF59-adjuvanted, and recombinant-HA seasonal influenza vaccination in older adults.
- Authors
Li, Athena P. Y.; Cohen, Carolyn A.; Leung, Nancy H. L.; Fang, Vicky J.; Gangappa, Shivaprakash; Sambhara, Suryaprakash; Levine, Min Z.; Iuliano, A. Danielle; Perera, Ranawaka A. P. M.; Ip, Dennis K. M.; Peiris, J. S. Malik; Thompson, Mark G.; Cowling, Benjamin J.; Valkenburg, Sophie A.
- Abstract
The vaccine efficacy of standard-dose seasonal inactivated influenza vaccines (S-IIV) can be improved by the use of vaccines with higher antigen content or adjuvants. We conducted a randomized controlled trial in older adults to compare cellular and antibody responses of S-IIV versus enhanced vaccines (eIIV): MF59-adjuvanted (A-eIIV), high-dose (H-eIIV), and recombinant-hemagglutinin (HA) (R-eIIV). All vaccines induced comparable H3-HA-specific IgG and elevated antibody-dependent cellular cytotoxicity (ADCC) activity at day 30 post vaccination. H3-HA-specific ADCC responses were greatest following H-eIIV. Only A-eIIV increased H3-HA-IgG avidity, HA-stalk IgG and ADCC activity. eIIVs also increased polyfunctional CD4+ and CD8+ T cell responses, while cellular immune responses were skewed toward single-cytokine-producing T cells among S-IIV subjects. Our study provides further immunological evidence for the preferential use of eIIVs in older adults as each vaccine platform had an advantage over the standard-dose vaccine in terms of NK cell activation, HA-stalk antibodies, and T cell responses.
- Subjects
INFLUENZA vaccines; VACCINE effectiveness; HEMAGGLUTININ; RECOMBINANT antibodies; ANTIBODY formation
- Publication
NPJ Vaccines, 2021, Vol 6, Issue 1, p1
- ISSN
2059-0105
- Publication type
Article
- DOI
10.1038/s41541-021-00289-5